{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T01:11:39Z","timestamp":1783905099287,"version":"3.55.0"},"reference-count":47,"publisher":"Walter de Gruyter GmbH","issue":"1","license":[{"start":{"date-parts":[[2020,3,1]],"date-time":"2020-03-01T00:00:00Z","timestamp":1583020800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/3.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,3,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec id=\"j_raon-2020-0011_s_005_w2aab3b8c47b1b7b1aab1c16b1Aa\">\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      Asbestos exposure is associated with increased risk of several diseases, including malignant mesothelioma (MM). Cell surface glycoprotein mesothelin is overexpressed in MM and serum soluble mesothelin-related peptides (SMRP) were already proposed as a diagnostic or prognostic biomarker in MM. However, interindividual variability in serum SMRP levels limits the clinical usefulness. Our primary objective was to investigate the influence of\n                      <jats:italic>MSLN<\/jats:italic>\n                      rs1057147 on serum SMRP levels in asbestos-exposed subjects and patients with asbestos-related diseases as well as on survival in MM.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_raon-2020-0011_s_006_w2aab3b8c47b1b7b1aab1c16b2Aa\">\n                    <jats:title>Subjects and methods<\/jats:title>\n                    <jats:p>\n                      Among 782 asbestos-exposed subjects and patients with asbestos-related diseases, 154 had MM. Serum SMRP levels were determined using sandwich enzyme-linked immunosorbent assay. All subjects were genotyped for\n                      <jats:italic>MSLN<\/jats:italic>\n                      rs1057147 polymorphism using competitive allele-specific polymerase chain reaction. Nonparametric tests, logistic and Cox regression were used in statistical analysis to compare different subject groups.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_raon-2020-0011_s_007_w2aab3b8c47b1b7b1aab1c16b3Aa\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      MM patients had significantly higher SMRP levels than all other subjects (\n                      <jats:italic>p<\/jats:italic>\n                      &lt; 0.001). Compared to wild-type\n                      <jats:italic>MSLN<\/jats:italic>\n                      rs1057147 genotype, both heterozygotes and carriers of two polymorphic alleles had significantly higher SMRP levels among subjects without MM (\n                      <jats:italic>p<\/jats:italic>\n                      &lt; 0.001), but not in MM patients (\n                      <jats:italic>p<\/jats:italic>\n                      = 0.424). If genotype information was included, specificity of SMRP increased from 88.5% to 92.7% for the optimal cutoff value. Overall survival was significantly shorter in MM patients carrying at least one polymorphic rs1057147 allele (HR = 1.72, 95% CI = 1.15-2.55,\n                      <jats:italic>p<\/jats:italic>\n                      = 0.008).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_raon-2020-0011_s_008_w2aab3b8c47b1b7b1aab1c16b4Aa\">\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>\n                      <jats:italic>MSLN<\/jats:italic>\n                      genetic variability affects serum SMRP levels and was associated with shorter survival of MM patients. Combination of genetic and serum factors could therefore serve as a better diagnostic or prognostic biomarker in MM patients.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.2478\/raon-2020-0011","type":"journal-article","created":{"date-parts":[[2020,3,18]],"date-time":"2020-03-18T09:34:19Z","timestamp":1584524059000},"page":"86-95","source":"Crossref","is-referenced-by-count":16,"title":["Evaluation of soluble mesothelin-related peptides and MSLN genetic variability in asbestos-related diseases"],"prefix":"10.2478","volume":"54","author":[{"given":"Katja","family":"Goricar","sequence":"first","affiliation":[{"name":"Pharmacogenetics Laboratory, Institute of Biochemistry, Faculty of Medicine, University of Ljubljana , Ljubljana , Slovenia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Viljem","family":"Kovac","sequence":"additional","affiliation":[{"name":"Institute of Oncology Ljubljana , Ljubljana , Slovenia"},{"name":"Faculty of Medicine, University of Ljubljana , Ljubljana , Slovenia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Metoda","family":"Dodic-Fikfak","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, University of Ljubljana , Ljubljana , Slovenia"},{"name":"Clinical Institute of Occupational Medicine, University Medical Centre Ljubljana , Ljubljana , Slovenia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vita","family":"Dolzan","sequence":"additional","affiliation":[{"name":"Pharmacogenetics Laboratory, Institute of Biochemistry, Faculty of Medicine, University of Ljubljana , Ljubljana , Slovenia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alenka","family":"Franko","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, University of Ljubljana , Ljubljana , Slovenia"},{"name":"Clinical Institute of Occupational Medicine, University Medical Centre Ljubljana , Ljubljana , Slovenia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"374","published-online":{"date-parts":[[2020,3,7]]},"reference":[{"key":"2026071212044702636_j_raon-2020-0011_ref_001_w2aab3b8c47b1b7b1ab2b1b1Aa","doi-asserted-by":"crossref","unstructured":"Johnen G, Chapman SJ, Cookson WO, Musk AW, Lee YC. Benign asbestos pleural diseases. Curr Opin Pulm Med 2003; 9: 266-71. doi: 10.1097\/00063198-200307000-00004","DOI":"10.1097\/00063198-200307000-00004"},{"key":"2026071212044702636_j_raon-2020-0011_ref_002_w2aab3b8c47b1b7b1ab2b1b2Aa","unstructured":"IARC monographs on the evaluation of the carcinogenic risk of chemicals to man: asbestos. IARC Monogr Eval Carcinog Risk Chem Man 1977; 14: 1-106. PMID: 863456"},{"key":"2026071212044702636_j_raon-2020-0011_ref_003_w2aab3b8c47b1b7b1ab2b1b3Aa","doi-asserted-by":"crossref","unstructured":"Robinson BWS, Lake RA. Medical progress \u2013 advances in malignant mesothelioma. N Engl J Med 2005; 353: 1591-603. doi: 10.1056\/NEJMra050152","DOI":"10.1056\/NEJMra050152"},{"key":"2026071212044702636_j_raon-2020-0011_ref_004_w2aab3b8c47b1b7b1ab2b1b4Aa","doi-asserted-by":"crossref","unstructured":"Kovac V, Zwitter M, Zagar T. Improved survival after introduction of chemotherapy for malignant pleural mesothelioma in Slovenia: population-based survey of 444 patients. Radiol Oncol 2012; 46: 136-44. doi: 10.2478\/ v10019-012-0032-0","DOI":"10.2478\/v10019-012-0032-0"},{"key":"2026071212044702636_j_raon-2020-0011_ref_005_w2aab3b8c47b1b7b1ab2b1b5Aa","doi-asserted-by":"crossref","unstructured":"Damhuis RA, Schroten C, Burgers JA. Population-based survival for malignant mesothelioma after introduction of novel chemotherapy. Eur Respir J 2012; 40: 185-9. doi: 10.1183\/09031936.00153611","DOI":"10.1183\/09031936.00153611"},{"key":"2026071212044702636_j_raon-2020-0011_ref_006_w2aab3b8c47b1b7b1ab2b1b6Aa","doi-asserted-by":"crossref","unstructured":"Helland A, Solberg S, Brustugun OT. Incidence and survival of malignant pleural mesothelioma in norway: a population-based study of 1686 cases. J Thorac Oncol 2012; 7: 1858-61. doi: 10.1097\/JTO.0b013e318275b346","DOI":"10.1097\/JTO.0b013e318275b346"},{"key":"2026071212044702636_j_raon-2020-0011_ref_007_w2aab3b8c47b1b7b1ab2b1b7Aa","doi-asserted-by":"crossref","unstructured":"Tomasetti M, Santarelli L. Biomarkers for early detection of malignant mesothelioma: diagnostic and therapeutic application. Cancers 2010; 2: 523-48. doi: 10.3390\/cancers2020523","DOI":"10.3390\/cancers2020523"},{"key":"2026071212044702636_j_raon-2020-0011_ref_008_w2aab3b8c47b1b7b1ab2b1b8Aa","doi-asserted-by":"crossref","unstructured":"Robinson BW, Creaney J, Lake R, Nowak A, Musk AW, de Klerk N, et al. Mesothelin-family proteins and diagnosis of mesothelioma. Lancet 2003; 362: 1612-6. doi: 10.1016\/S0140-6736(03)14794-0","DOI":"10.1016\/S0140-6736(03)14794-0"},{"key":"2026071212044702636_j_raon-2020-0011_ref_009_w2aab3b8c47b1b7b1ab2b1b9Aa","doi-asserted-by":"crossref","unstructured":"Husain AN, Colby TV, Ord\u00f3\u00f1ez NG, Allen TC, Attanoos RL, Beasley MB, et al. Guidelines for Pathologic Diagnosis of Malignant Mesothelioma 2017 Update of the Consensus Statement From the International Mesothelioma Interest Group. Arch Pathol Lab Med 2018; 14: 89-108. doi: 10.5858\/ arpa.2017-0124-RA","DOI":"10.5858\/arpa.2017-0124-RA"},{"key":"2026071212044702636_j_raon-2020-0011_ref_010_w2aab3b8c47b1b7b1ab2b1c10Aa","doi-asserted-by":"crossref","unstructured":"Ordonez NG. Value of mesothelin immunostaining in the diagnosis of mesothelioma. Mod Pathol 2003; 16: 192-7. doi: 10.1097\/01. MP.0000056981.16578.C3","DOI":"10.1097\/01.MP.0000056981.16578.C3"},{"key":"2026071212044702636_j_raon-2020-0011_ref_011_w2aab3b8c47b1b7b1ab2b1c11Aa","doi-asserted-by":"crossref","unstructured":"Creaney J, Olsen NJ, Brims F, Dick IM, Musk AW, de Klerk NH, et al. Serum mesothelin for early detection of asbestos-induced cancer malignant mesothelioma. Cancer Epidemiol Biomarkers Prev 2010; 19: 2238-46. doi: 10.1158\/1055-9965.EPI-10-0346","DOI":"10.1158\/1055-9965.EPI-10-0346"},{"key":"2026071212044702636_j_raon-2020-0011_ref_012_w2aab3b8c47b1b7b1ab2b1c12Aa","doi-asserted-by":"crossref","unstructured":"Hollevoet K, Reitsma JB, Creaney J, Grigoriu BD, Robinson BW, Scherpereel A, et al. Serum mesothelin for diagnosing malignant pleural mesothelioma: an individual patient data meta-analysis. J Clin Oncol 2012; 30: 1541-9. doi: 10.1200\/JCO.2011.39.6671","DOI":"10.1200\/JCO.2011.39.6671"},{"key":"2026071212044702636_j_raon-2020-0011_ref_013_w2aab3b8c47b1b7b1ab2b1c13Aa","doi-asserted-by":"crossref","unstructured":"Hollevoet K, Van Cleemput J, Thimpont J, De Vuyst P, Bosquee L, Nackaerts K, et al. Serial measurements of mesothelioma serum biomarkers in asbestos-exposed individuals: a prospective longitudinal cohort study. J Thorac Oncol 2011; 6: 889-95. doi: 10.1097\/JTO.0b013e31820db377","DOI":"10.1097\/JTO.0b013e31820db377"},{"key":"2026071212044702636_j_raon-2020-0011_ref_014_w2aab3b8c47b1b7b1ab2b1c14Aa","doi-asserted-by":"crossref","unstructured":"Cui A, Jin XG, Zhai K, Tong ZH, Shi HZ. Diagnostic values of soluble mesothelin-related peptides for malignant pleural mesothelioma: updated meta-analysis. BMJ open 2014; 4: e004145. doi: 10.1136\/bmjopen-2013-004145","DOI":"10.1136\/bmjopen-2013-004145"},{"key":"2026071212044702636_j_raon-2020-0011_ref_015_w2aab3b8c47b1b7b1ab2b1c15Aa","doi-asserted-by":"crossref","unstructured":"Hassan R, Thomas A, Alewine C, Le DT, Jaffee EM, Pastan I. Mesothelin immunotherapy for cancer: ready for prime time? J Clin Oncol 2016; 34: 4171-9. doi: 10.1200\/JCO.2016.68.3672","DOI":"10.1200\/JCO.2016.68.3672"},{"key":"2026071212044702636_j_raon-2020-0011_ref_016_w2aab3b8c47b1b7b1ab2b1c16Aa","doi-asserted-by":"crossref","unstructured":"Gillezeau C, van Gerwen M, Ramos J, Liu B, Flores R, Taioli E. Biomarkers for malignant pleural mesothelioma: a meta-analysis. Carcinogenesis 2019. doi: 10.1093\/carcin\/bgz103","DOI":"10.1093\/carcin\/bgz103"},{"key":"2026071212044702636_j_raon-2020-0011_ref_017_w2aab3b8c47b1b7b1ab2b1c17Aa","doi-asserted-by":"crossref","unstructured":"Robinson BW, Creaney J, Lake R, Nowak A, Musk AW, de Klerk N, et al. Soluble mesothelin-related protein--a blood test for mesothelioma. Lung Cancer 2005; 49(Suppl 1): S109-11. doi: 10.1016\/j.lungcan.2005.03.020","DOI":"10.1016\/j.lungcan.2005.03.020"},{"key":"2026071212044702636_j_raon-2020-0011_ref_018_w2aab3b8c47b1b7b1ab2b1c18Aa","doi-asserted-by":"crossref","unstructured":"Tian L, Zeng R, Wang X, Shen C, Lai Y, Wang M, et al. Prognostic significance of soluble mesothelin in malignant pleural mesothelioma: a meta-analysis. Oncotarget 2017; 8: 46425-35. doi: 10.18632\/oncotarget.17436","DOI":"10.18632\/oncotarget.17436"},{"key":"2026071212044702636_j_raon-2020-0011_ref_019_w2aab3b8c47b1b7b1ab2b1c19Aa","doi-asserted-by":"crossref","unstructured":"He X, Wang L, Riedel H, Wang K, Yang Y, Dinu CZ, et al. Mesothelin promotes epithelial-to-mesenchymal transition and tumorigenicity of human lung cancer and mesothelioma cells. Mol Cancer 2017; 16: 63. doi: 10.1186\/ s12943-017-0633-8","DOI":"10.1186\/s12943-017-0633-8"},{"key":"2026071212044702636_j_raon-2020-0011_ref_020_w2aab3b8c47b1b7b1ab2b1c20Aa","doi-asserted-by":"crossref","unstructured":"Cristaudo A, Bonotti A, Simonini S, Bruno R, Foddis R. Soluble markers for diagnosis of malignant pleural mesothelioma. Biomark Med 2011; 5: 261-73. doi: 10.2217\/bmm.11.18","DOI":"10.2217\/bmm.11.18"},{"key":"2026071212044702636_j_raon-2020-0011_ref_021_w2aab3b8c47b1b7b1ab2b1c21Aa","doi-asserted-by":"crossref","unstructured":"Franko A, Dolzan V, Kovac V, Arneric N, Dodic-Fikfak M. Soluble mesothelin-related peptides levels in patients with malignant mesothelioma. Dis Markers 2012; 32: 123-31. doi: 10.3233\/DMA-2011-0866","DOI":"10.1155\/2012\/430689"},{"key":"2026071212044702636_j_raon-2020-0011_ref_022_w2aab3b8c47b1b7b1ab2b1c22Aa","doi-asserted-by":"crossref","unstructured":"de Fonseka D, Arnold DT, Stadon L, Morley A, Keenan E, Darby M, et al. A prospective study to investigate the role of serial serum mesothelin in monitoring mesothelioma. BMC Cancer 2018; 18: 199. doi: 10.1186\/ s12885-018-4113-3","DOI":"10.1186\/s12885-018-4113-3"},{"key":"2026071212044702636_j_raon-2020-0011_ref_023_w2aab3b8c47b1b7b1ab2b1c23Aa","doi-asserted-by":"crossref","unstructured":"Linch M, Gennatas S, Kazikin S, Iqbal J, Gunapala R, Priest K, et al. A serum mesothelin level is a prognostic indicator for patients with malignant mesothelioma in routine clinical practice. BMC Cancer 2014; 14: 674. doi: 10.1186\/1471-2407-14-674","DOI":"10.1186\/1471-2407-14-674"},{"key":"2026071212044702636_j_raon-2020-0011_ref_024_w2aab3b8c47b1b7b1ab2b1c24Aa","doi-asserted-by":"crossref","unstructured":"Li ZQ, Verch T, Allard WJ. MESOMARK((R)) in vitro diagnostic test for mesothelioma. Expert Opin Med Diagn 2007; 1: 137-42. doi: 10.1517\/17530059.1.1.137","DOI":"10.1517\/17530059.1.1.137"},{"key":"2026071212044702636_j_raon-2020-0011_ref_025_w2aab3b8c47b1b7b1ab2b1c25Aa","doi-asserted-by":"crossref","unstructured":"Cristaudo A, Foddis R, Bonotti A, Simonini S, Vivaldi A, Guglielmi G, et al. Two novel polymorphisms in 5\u2019 flanking region of the mesothelin gene are associated with soluble mesothelin-related peptide (SMRP) levels. Int J Biol Markers 2011; 26: 117-23. doi: 10.5301\/JBM.2011.8332","DOI":"10.5301\/JBM.2011.8332"},{"key":"2026071212044702636_j_raon-2020-0011_ref_026_w2aab3b8c47b1b7b1ab2b1c26Aa","doi-asserted-by":"crossref","unstructured":"De Santi C, Pucci P, Bonotti A, Melaiu O, Cipollini M, Silvestri R, et al. Mesothelin promoter variants are associated with increased soluble mesothelin-related peptide levels in asbestos-exposed individuals. Occup Environ Med 2017; 74: 456-63. doi: 10.1136\/oemed-2016-104024","DOI":"10.1136\/oemed-2016-104024"},{"key":"2026071212044702636_j_raon-2020-0011_ref_027_w2aab3b8c47b1b7b1ab2b1c27Aa","doi-asserted-by":"crossref","unstructured":"Cristaudo A, Foddis R, Bonotti A, Simonini S, Vivaldi A, Guglielmi G, et al. Polymorphisms in the putative micro-RNA-binding sites of mesothelin gene are associated with serum levels of mesothelin-related protein. Occup Environ Med 2010; 67: 233-6. doi: 10.1136\/oem.2009.049205","DOI":"10.1136\/oem.2009.049205"},{"key":"2026071212044702636_j_raon-2020-0011_ref_028_w2aab3b8c47b1b7b1ab2b1c28Aa","doi-asserted-by":"crossref","unstructured":"Garritano S, De Santi C, Silvestri R, Melaiu O, Cipollini M, Barone E, et al. A common polymorphism within MSLN affects miR-611 binding site and soluble mesothelin levels in healthy people. J Thorac Oncol 2014; 9: 1662-8. doi: 10.1097\/JTO.0000000000000322","DOI":"10.1097\/JTO.0000000000000322"},{"key":"2026071212044702636_j_raon-2020-0011_ref_029_w2aab3b8c47b1b7b1ab2b1c29Aa","doi-asserted-by":"crossref","unstructured":"Tossavainen A. Asbestos, asbestosis, and cancer: the Helsinki criteria for diagnosis and attribution. Scand J Work Environ Health 1997; 23: 311-6. doi: 10.5271\/sjweh.226","DOI":"10.5271\/sjweh.226"},{"key":"2026071212044702636_j_raon-2020-0011_ref_030_w2aab3b8c47b1b7b1ab2b1c30Aa","doi-asserted-by":"crossref","unstructured":"American Thoracic Sociaty Document. Diagnosis and initial management of nonmalignant diseases related to asbestos. Am J Respir Crit Care Med 2004; 170: 691-715. doi: 10.1164\/rccm.200310-1436ST","DOI":"10.1164\/rccm.200310-1436ST"},{"key":"2026071212044702636_j_raon-2020-0011_ref_031_w2aab3b8c47b1b7b1ab2b1c31Aa","unstructured":"Ferris BG. Epidemiology Standardization Project (American Thoracic Society). Am Rev Respir Dis 1978; 118: 1-120. PMID: 742764"},{"key":"2026071212044702636_j_raon-2020-0011_ref_032_w2aab3b8c47b1b7b1ab2b1c32Aa","unstructured":"Dodic Fikfak M, Kriebel D, Quinn MM, Eisen EA, Wegman DH. A case control study of lung cancer and exposure to chrysotile and amphibole at a slovenian asbestos-cement plant. Ann Occup Hyg 2007; 51: 261-8. doi: 10.1093\/ annhyg\/mem003"},{"key":"2026071212044702636_j_raon-2020-0011_ref_033_w2aab3b8c47b1b7b1ab2b1c33Aa","doi-asserted-by":"crossref","unstructured":"Bruno F, Baratti D, Martinetti A, Morelli D, Sottotetti E, Bonini C, et al. Mesothelin and osteopontin as circulating markers of diffuse malignant peritoneal mesothelioma: A preliminary study. Ejso-Eur J Surg Onc 2018; 44: 792-8. doi: 10.1016\/j.ejso.2018.02.010","DOI":"10.1016\/j.ejso.2018.02.010"},{"key":"2026071212044702636_j_raon-2020-0011_ref_034_w2aab3b8c47b1b7b1ab2b1c34Aa","doi-asserted-by":"crossref","unstructured":"Grigoriu BD, Chahine B, Vachani A, Gey T, Conti M, Sterman DH, et al. Kinetics of soluble mesothelin in patients with malignant pleural mesothelioma during treatment. Am J Respir Crit Care Med 2009; 179: 950-4. doi: 10.1164\/rccm.200807-1125OC","DOI":"10.1164\/rccm.200807-1125OC"},{"key":"2026071212044702636_j_raon-2020-0011_ref_035_w2aab3b8c47b1b7b1ab2b1c35Aa","doi-asserted-by":"crossref","unstructured":"Arnold DT, De Fonseka D, Hamilton FW, Rahman NM, Maskell NA. Prognostication and monitoring of mesothelioma using biomarkers: a systematic review. Br J Cancer 2017; 116: 731-41. doi: 10.1038\/bjc.2017.22","DOI":"10.1038\/bjc.2017.22"},{"key":"2026071212044702636_j_raon-2020-0011_ref_036_w2aab3b8c47b1b7b1ab2b1c36Aa","doi-asserted-by":"crossref","unstructured":"Fontana V, Vigani A, Pistillo MP, Giannoni U, Rosemberg I, Canessa PA, et al. The correlation of serum mesothelin level with pleural thickness in malignant pleural mesothelioma makes it a valuable tool for monitoring tumor progression. J Thorac Oncol 2019; 14: e92-e4. doi: 10.1016\/j. jtho.2018.12.026","DOI":"10.1016\/j.jtho.2018.12.026"},{"key":"2026071212044702636_j_raon-2020-0011_ref_037_w2aab3b8c47b1b7b1ab2b1c37Aa","doi-asserted-by":"crossref","unstructured":"Park EK, Wilson D, Yates DH. A predictive equation to adjust for clinical variables in soluble mesothelin-related protein (SMRP) levels. Clin Chem Lab Med 2012; 50: 2199-204. doi: 10.1515\/cclm-2012-0314","DOI":"10.1515\/cclm-2012-0314"},{"key":"2026071212044702636_j_raon-2020-0011_ref_038_w2aab3b8c47b1b7b1ab2b1c38Aa","doi-asserted-by":"crossref","unstructured":"Filiberti R, Marroni P, Mencoboni M, Mortara V, Caruso P, Cioe A, et al. Individual predictors of increased serum mesothelin in asbestos-exposed workers. Med Oncol 2013; 30: 422. doi: 10.1007\/s12032-012-0422-6","DOI":"10.1007\/s12032-012-0422-6"},{"key":"2026071212044702636_j_raon-2020-0011_ref_039_w2aab3b8c47b1b7b1ab2b1c39Aa","doi-asserted-by":"crossref","unstructured":"Pass HI, Levin SM, Harbut MR, Melamed J, Chiriboga L, Donington J, et al. Fibulin-3 as a blood and effusion biomarker for pleural mesothelioma. N Engl J Med 2012; 367: 1417-27. doi: 10.1056\/NEJMoa1115050","DOI":"10.1056\/NEJMoa1115050"},{"key":"2026071212044702636_j_raon-2020-0011_ref_040_w2aab3b8c47b1b7b1ab2b1c40Aa","doi-asserted-by":"crossref","unstructured":"Kovac V, Dodic-Fikfak M, Arneric N, Dolzan V, Franko A. Fibulin-3 as a bio-marker of response to treatment in malignant mesothelioma. Radiol Oncol 2015; 49: 279-85. doi: 10.1515\/raon-2015-0019","DOI":"10.1515\/raon-2015-0019"},{"key":"2026071212044702636_j_raon-2020-0011_ref_041_w2aab3b8c47b1b7b1ab2b1c41Aa","doi-asserted-by":"crossref","unstructured":"Cristaudo A, Bonotti A, Guglielmi G, Fallahi P, Foddis R. Serum mesothelin and other biomarkers: what have we learned in the last decade? J Thorac Dis 2018; 10: S353-9. doi: 10.21037\/jtd.2017.10.132","DOI":"10.21037\/jtd.2017.10.132"},{"key":"2026071212044702636_j_raon-2020-0011_ref_042_w2aab3b8c47b1b7b1ab2b1c42Aa","doi-asserted-by":"crossref","unstructured":"Creaney J, Robinson BWS. Malignant mesothelioma biomarkers: from discovery to use in clinical practice for diagnosis, monitoring, screening, and treatment. Chest 2017; 152: 143-9. doi: 10.1016\/j.chest.2016.12.004","DOI":"10.1016\/j.chest.2016.12.004"},{"key":"2026071212044702636_j_raon-2020-0011_ref_043_w2aab3b8c47b1b7b1ab2b1c43Aa","doi-asserted-by":"crossref","unstructured":"Kirschner MB, Cheng YY, Badrian B, Kao SC, Creaney J, Edelman JJ, et al. Increased circulating miR-625-3p: a potential biomarker for patients with malignant pleural mesothelioma. J Thorac Oncol 2012; 7: 1184-91. doi: 10.1097\/JTO.0b013e3182572e83","DOI":"10.1097\/JTO.0b013e3182572e83"},{"key":"2026071212044702636_j_raon-2020-0011_ref_044_w2aab3b8c47b1b7b1ab2b1c44Aa","doi-asserted-by":"crossref","unstructured":"Cristaudo A, Bonotti A, Simonini S, Vivaldi A, Guglielmi G, Ambrosino N, et al. Combined serum mesothelin and plasma osteopontin measurements in malignant pleural mesothelioma. J Thorac Oncol 2011; 6: 1587-93. doi: 10.1097\/JTO.0b013e31821e1c08","DOI":"10.1097\/JTO.0b013e31821e1c08"},{"key":"2026071212044702636_j_raon-2020-0011_ref_045_w2aab3b8c47b1b7b1ab2b1c45Aa","doi-asserted-by":"crossref","unstructured":"Hoda MA, Dong Y, Rozsas A, Klikovits T, Laszlo V, Ghanim B, et al. Circulating activin A is a novel prognostic biomarker in malignant pleural mesothelioma - a multi-institutional study. Eur J Cancer 2016; 63: 64-73. doi: 10.1016\/j.ejca.2016.04.018","DOI":"10.1016\/j.ejca.2016.04.018"},{"key":"2026071212044702636_j_raon-2020-0011_ref_046_w2aab3b8c47b1b7b1ab2b1c46Aa","doi-asserted-by":"crossref","unstructured":"Foddis R, Bonotti A, Landi S, Fallahi P, Guglielmi G, Cristaudo A. Biomarkers in the prevention and follow-up of workers exposed to asbestos. J Thorac Dis 2018; 10: S360-8. doi: 10.21037\/jtd.2017.12.17","DOI":"10.21037\/jtd.2017.12.17"},{"key":"2026071212044702636_j_raon-2020-0011_ref_047_w2aab3b8c47b1b7b1ab2b1c47Aa","doi-asserted-by":"crossref","unstructured":"Santarelli L, Staffolani S, Strafella E, Nocchi L, Manzella N, Grossi P, et al. Combined circulating epigenetic markers to improve mesothelin performance in the diagnosis of malignant mesothelioma. Lung Cancer 2015; 90: 457-64. doi: 10.1016\/j.lungcan.2015.09.021","DOI":"10.1016\/j.lungcan.2015.09.021"}],"container-title":["Radiology and Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/content.sciendo.com\/view\/journals\/raon\/54\/1\/article-p86.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/reference-global.com\/pdf\/10.2478\/raon-2020-0011","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T00:40:50Z","timestamp":1783903250000},"score":1,"resource":{"primary":{"URL":"https:\/\/reference-global.com\/article\/10.2478\/raon-2020-0011"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3,1]]},"references-count":47,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,3,7]]},"published-print":{"date-parts":[[2020,3,7]]}},"alternative-id":["10.2478\/raon-2020-0011"],"URL":"https:\/\/doi.org\/10.2478\/raon-2020-0011","relation":{},"ISSN":["1581-3207"],"issn-type":[{"value":"1581-3207","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,3,1]]}}}